Drug Profile
Morphine extended release
Alternative Names: KADIANLatest Information Update: 16 Mar 2022
Price :
$50
*
At a glance
- Originator Faulding Laboratories
- Developer Alpharma
- Class Morphinans; Opioid analgesics; Small molecules
- Mechanism of Action Opioid receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Pain
- Phase III Opioid-related disorders
Most Recent Events
- 27 Jan 2022 Mayne Pharma International terminates a phase-III pRESTO trial as study was unable to proceed per protocol due to COVID-19 precautions, in Opioid-related disorders in Canada (PO) (NCT03948464)
- 08 May 2020 Allergan has been acquired and merged into AbbVie
- 06 Dec 2019 Phase-III clinical trials in Opioid-related disorders in Canada (PO) (NCT03948464)